Fertility-sparing treatment of endometrial cancer - is it possible? A case study
DOI:
https://doi.org/10.12775/JEHS.2022.12.07.057Keywords
endometrial cancer, fertility, oncologyAbstract
Background: Endometrial cancer is the most common gynecological malignant neoplasm, which occurs in the majority of cases postmenopausally. The current standard of treatment is surgical - total hysterectomy. However, it may also occur in younger patients, who are planning pregnancy and want to choose fertility-sparing treatment. For those patients oral high dose progestin therapy with or without hysteroscopic resection should be proposed. It is usually a good option for women with well-differentiated (G1) cancers. For patients with higher grade (G2, G3) or contraindications to progestins, fertility-sparing treatment of endometrial cancer seems impossible.
Case report: We present the case of a 34-year old woman diagnosed gynecologically due to abnormal bleeding from the genital tract. Based on USG, she was diagnosed with endometrial polyp. As a treatment, hysteroscopic resection was performed. In the histopathological evaluation G2 endometrial cancer was diagnosed. The standard approach would be a total hysterectomy, but the patient was interested in fertility-sparing options. Due to contraindications to progestins a total hysteroscopic resection was performed counseling the patient about the risks of a novel approach. Histopathology revealed no residual disease and no other lesions during the first year of observations occurred.
Conclusion: Total hysteroscopic resection without further progestin therapy may offer the possibility to treat G2 endometrial cancer despite contraindications to the administration of progestins. Our case report should also encourage further evaluation of fertility-sparing management of endometrial cancer with higher than G1 grade.
References
Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet (London, England) 2005;366:491–505. https://doi.org/10.1016/S0140-6736(05)67063-8.
Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet Oncol 2014;15. https://doi.org/10.1016/S1470-2045(13)70591-6.
Prat J, Gallardo A, Cuatrecasas M, Catasús L. Endometrial carcinoma: pathology and genetics. Pathology 2007;39:72–87. https://doi.org/10.1080/00313020601136153.
PDQ Screening and Prevention Editorial Board. Endometrial Cancer Prevention (PDQ®): Health Professional Version. PDQ Cancer Inf Summ 2002.
Lee YC, Lheureux S, Oza AM. Treatment strategies for endometrial cancer: current practice and perspective. Curr Opin Obstet Gynecol 2017;29:47–58. https://doi.org/10.1097/GCO.0000000000000338.
Clarke-Pearson DL, Geller EJ. Complications of hysterectomy. Obstet Gynecol 2013;121:654–73. https://doi.org/10.1097/AOG.0B013E3182841594.
Maggiore ULR, Khamisy-Farah R, Bragazzi NL, Bogani G, Martinelli F, Lopez S, et al. Fertility-Sparing Treatment of Patients with Endometrial Cancer: A Review of the Literature. J Clin Med 2021, Vol 10, Page 4784 2021;10:4784. https://doi.org/10.3390/JCM10204784.
Won S, Kim MK, Seong SJ. Fertility-sparing treatment in women with endometrial cancer. Clin Exp Reprod Med 2020;47:237–44. https://doi.org/10.5653/CERM.2020.03629.
Garzon S, Uccella S, Zorzato PC, Bosco M, Franchi MP, Student V, et al. Fertility-sparing management for endometrial cancer: review of the literature. Minerva Med 2021;112:55–69. https://doi.org/10.23736/S0026-4806.20.07072-X.
Falcone F, Laurelli G, Losito S, Di Napoli M, Granata V, Greggi S. Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer. J Gynecol Oncol 2017;28:2. https://doi.org/10.3802/JGO.2017.28.E2.
Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 2021;31:12–39. https://doi.org/10.1136/IJGC-2020-002230.
Park JY, Kim DY, Kim TJ, Kim JW, Kim JH, Kim YM, et al. Hormonal therapy for women with stage IA endometrial cancer of all grades. Obstet Gynecol 2013;122:7–14. https://doi.org/10.1097/AOG.0B013E3182964CE3.
Casadio P, Guasina F, Paradisi R, Leggieri C, Caprara G, Seracchioli R. Fertility‐Sparing Treatment of Endometrial Cancer with Initial Infiltration of Myometrium by Resectoscopic Surgery: A Pilot Study. Oncologist 2018;23:478. https://doi.org/10.1634/THEONCOLOGIST.2017-0285.
KOSKAS M, YAZBECK C, WALKER F, CLOUQUEUR E, AGOSTINI A, RUAT S, et al. Fertility-sparing Management of Grade 2 and 3 Endometrial Adenocarcinomas. Anticancer Res 2011;31.
Chae SH, Shim SH, Lee SJ, Lee JY, Kim SN, Kang SB. Pregnancy and oncologic outcomes after fertility-sparing management for early stage endometrioid endometrial cancer. Int J Gynecol Cancer 2019;29:77–85. https://doi.org/10.1136/IJGC-2018-000036.
Wang YQ, Zhou R, Xu LJ, Xia M, Lu Q, Liu GL, et al. [Analysis of prognosis and pregnancy outcomes of fertility-preserving treatment for patients with stage Ⅰa, grade 2 endometrial cancer]. Zhonghua Fu Chan Ke Za Zhi 2020;55:327–32. https://doi.org/10.3760/CMA.J.CN112141-20200118-00047.
Shan W, Wu P, Yang B, Zhang H, Sun L, Lv Q, et al. Conservative management of grade 2 stage IA endometrial carcinoma and literature review. J Obstet Gynaecol Res 2021;47:984–91. https://doi.org/10.1111/JOG.14646.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Milena Leziak, Klaudia Żak, Małgorzata Satora, Justyna Szpyra, Natalia Kluz, Krzysztof Kułak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 422
Number of citations: 0